GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
What happened
FDA reviewed GenLabMeds’ website at https://genlabmeds.com in August 2025 and found it offered compounded retatrutide, semaglutide, and tirzepatide drug products. FDA said the compounded retatrutide products are unapproved and misbranded because retatrutide is not an allowed raw ingredient under the special compounding exemptions in sections 503A or 503B. FDA also said website claims falsely imply the compounded products are the same as FDA-approved drugs such as Mounjaro, Zepbound, Ozempic, and Wegovy.
What FDA found
GenLabMeds’ compounded retatrutide products are unapproved new drugs because no FDA-approved application is in effect for them.
FDCA §§ 505(a), 301(d) [21 U.S.C. §§ 355(a), 331(d)]The retatrutide products are misbranded because their labeling does not bear adequate directions for use for conditions that laypeople cannot self-diagnose and treat.
FDCA § 502(f)(1), § 301(a) [21 U.S.C. §§ 352(f)(1), 331(a)]The compounded retatrutide products do not qualify for the special compounding exemptions in sections 503A or 503B because retatrutide is not an allowed raw drug ingredient, is not part of an FDA-approved drug, and is not on the drug shortage list.
FDCA §§ 503A(b)(1)(A)(i), 503B(a)(2)(A)(i) [21 U.S.C. §§ 353a(b)(1)(A)(i), 353b(a)(2)(A)]The website claims are false or misleading because they suggest the compounded products are the same as FDA-approved Mounjaro, Zepbound, Ozempic, or Wegovy and cite an FDA-approved dosing schedule for retatrutide.
FDCA §§ 502(a), 502(bb), 301(a) [21 U.S.C. §§ 352(a), 352(bb), 331(a)]Receipt in interstate commerce of misbranded drugs, and delivery or proffered delivery of them, is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells GenLabMeds to take immediate action, including ceasing the misleading claims, and to send a written response to CDER’s Office of Compounding Quality and Compliance within 15 working days of receipt. The response should describe specific steps taken to address the violations, prevent recurrence, and include related documentation.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and outsourcing facilities
- consumers and brands comparing compounded products with FDA-approved drugs
This is a summary. Read the original letter on fda.gov.